New Insights into Alzheimer's Disease : Novel Pathogenesis, Drug Target and Delivery

Alzheimer's disease (AD), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (Aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. However, the developed medicines targeting Aβ and tau have not obtained ideal clinical efficacy, which raises a challenge to the hypothesis that AD is Aβ cascade-induced. A critical problem of AD pathogenesis is which endogenous factor induces Aβ aggregation and tau phosphorylation. Recently, age-associated endogenous formaldehyde has been suggested to be a direct trigger for Aβ- and tau-related pathology. Another key issue is whether or not AD drugs are successfully delivered to the damaged neurons. Both the blood-brain barrier (BBB) and extracellular space (ECS) are the barriers for drug delivery. Unexpectedly, Aβ-related SP deposition in ECS slows down or stops interstitial fluid drainage in AD, which is the direct reason for drug delivery failure. Here, we propose a new pathogenesis and perspectives on the direction of AD drug development and drug delivery: (1) aging-related formaldehyde is a direct trigger for Aβ assembly and tau hyperphosphorylation, and the new target for AD therapy is formaldehyde; (2) nano-packaging and physical therapy may be the promising strategy for increasing BBB permeability and accelerating interstitial fluid drainage.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:15

Enthalten in:

Pharmaceutics - 15(2023), 4 vom: 03. Apr.

Sprache:

Englisch

Beteiligte Personen:

Chen, Haishu [VerfasserIn]
Xu, Jinan [VerfasserIn]
Xu, Hanyuan [VerfasserIn]
Luo, Tiancheng [VerfasserIn]
Li, Yihao [VerfasserIn]
Jiang, Ke [VerfasserIn]
Shentu, Yangping [VerfasserIn]
Tong, Zhiqian [VerfasserIn]

Links:

Volltext

Themen:

Alzheimer’s disease
Blood–brain barrier
Drug delivery
Extracellular space
Formaldehyde
Interstitial fluid
Journal Article
Review

Anmerkungen:

Date Revised 01.05.2023

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/pharmaceutics15041133

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM356151956